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SulTlmary 
The ligand for CD40  (CD40L)  is expressed on the surface of activated CD4 + T  cells  and its 
role in T-B cell collaborations and thymus-dependent humoral immunity is well established. 
Recently, by generating CD40L-knockout mice, we have confirmed its previously described 
role in humoral immunity and defined another important function of this molecule in the in 
vivo clonal expansion of antigen-specific CD4 + T cells. Here, we investigated the potential in vivo 
role of CD40L in antiviral immunity by examining the immune response mounted by CD40L- 
deficient mice following infection with lymphocytic choriomeningitis virus (LCMV), Pichinde 
virus,  or vesicular stomatitis virus.  Humoral immune responses of CD40L-deficient  mice to 
these viruses were severely compromised, although moderate titres of antiviral IgM and some 
IgG2a were produced by virus-infected CD40L-deficient mice by a CD4 + T  cell-independent 
mechanism. By contrast, CD40L-deficient mice made strong primary CTL responses to all three 
viruses. Interestingly however, although memory CTL activity was detectable in CD40L-defi- 
cient mice two months after infection with LCMV, the memory CTL response was much less 
efficient than in wild-type mice. Together,  the  results show that CD40-CD40L interactions 
are required for strong antiviral humoral immune responses, and reveal a novel role for CD40L 
in the establishment and/or maintenance of CD8 + CTL memory. 
T 
he CD40 ligand  (CD40L, gp39, TBAM) 1 is a type II 
membrane glycoprotein whose extracellular domain is 
homologous to tumor necrosis factor (TNF)-e~ and -[3  (1, 
2).  This protein is expressed transiently on CD4 +  T  cells 
following activation in vitro or in vivo (3-5),  and weakly 
on  CD8 +  T  cells  following in vitro activation with  anti- 
CD3  or PMA/ionomycin  (1,  3, 4, 6, 7).  CD40L binds to 
CD40, a 50-kD member of the TNF receptor superfamily 
expressed  on  several immune  system cell  types including 
immature and mature B  lymphocytes, interdigitating  cells 
in the T  cell areas of secondary lymphoid organs, follicular 
dendritic  cells,  and  thymic  epithelium  (8).  On  B  cells, 
CD40 is an important triggering molecule through which 
mitogenic signals  can be delivered (8). 
Interactions between CD40L and CD40 on B  cells play 
a key role  in  the  development of thymus-dependent hu- 
1Abbreviations used in  this paper: ASC, antibody-secreting cell; CD40L, 
CD40 ligand; GP, glycoprotein; LCMV, lymphocytic  choriomeningitis 
virus; moi, multiplicity of infection; NP,  nucleoprotein; pfu, plaque- 
forming unit; PNA, peanut agglutinin; PV, Pichinde virus; VSV, vesicular 
stomatitis virus; W, vaccinia  virus. 
moral immune responses, as they mediate the cognate in- 
teractions between helper T  cells and B cells that are essential 
for the induction of B  cell activation and immunoglobulin 
(Ig)  production  (1,  2, 7,  8, 9). Not only primary, but also 
secondary humoral  responses  are  dependent  on  CD40L- 
CD40 interactions: germinal center formation and the gen- 
eration of B  cell memory also fail to take place if CD40L- 
CD40  interactions  do  not  occur  (10-13).  In  addi:ion  to 
these roles in the generation and maintenance of humoral 
immunity to thymus-dependent antigens, it can be inferred 
from their sites  of expression that CD40L-CD40  interac- 
tions fikely also play other more diverse roles in the func- 
tioning of the immune system. For example, CD40L is ex- 
pressed on thymocytes, and unpublished  data reviewed in 
(14)  suggests that here it may play a role in thymic selec- 
tion. Moreover, our recent studies show a requirement of 
CD40L for in vivo priming ofCD4 + T  cells (15). 
To allow further study of the potential roles of CD40L 
in immune responses, CD40L-deficient mice have recently 
been generated by gene targeting (16,  17).  No significant 
alterations  in  lymphocyte  development  are  apparent  in 
these mice, and they possess normal distributions  and per- 
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have low levels of most circulating immunoglobulin isotypes, 
they  do  not  exhibit  the  spontaneous  hyper-IgM  (HIM) 
syndrome seen in humans with mutations in their CD40L 
gene  (16,  17). After immunization with inert antigens, the 
CD40L-deficient mice respond normally to  thymus-inde- 
pendent antigens, but have  a  decreased IgM response and 
fail altogether to produce an antigen-specific IgG1 response 
to thymus-dependent antigens. Moreover, they do not de- 
velop  germinal  centers  in  response  to  thymus-dependent 
antigens, suggesting they may have an inability to develop 
memory B  cell responses (16). 
We examined the immune response mounted by CD40L- 
deficient mice after infection with different viruses, includ- 
ing  the  arenaviruses  lymphocytic  choriomeningitis  virus 
(LCMV)  and Pichinde virus  (PV),  and vesicular stomatitis 
virus (VSV), a rhabdovirus. All of these viruses elicit strong 
cellular and  humoral  immune  responses  in  normal  mice. 
However, while arenavirus clearance is primarily mediated 
by the  CD8 +  MHC  class l-restricted antiviral cytotoxic 
T  lymphocyte  (CTL)  response  (18-21),  in  VSV-infected 
mice neutralizing antibody production plays a much more 
important  role  in  protection  (22-24).  CD40L-deficient 
mice  mounted  strong primary CTL  responses after infec- 
tion  with  all of these viruses,  and  cleared infectious virus 
from  the  periphery with  similar kinetics to  non-deficient 
control  animals.  In  addition  to  producing  some  antiviral 
antibody of the  IgM isotype,  CD40L-deficient  mice  also 
produced  virus-specific  IgG2a,  although  at  lower  levels 
than in non-deficient control animals; the latter occurred by 
a CD4-independent mechanism. The antiviral antibody pro- 
duction in virus-infected CD40L-deficient mice took place 
in the absence of germinal center formation and titres of vi- 
rus-specific antibody decreased  over  time;  further,  B  cell 
memory was  not established. Interestingly, while memory 
CTL activity could be detected in LCMV-infected CD40L- 
deficient mice, it was not present at as high a level in these 
animals  at  2  mo  after  infection  as  in  CD40L-expressing 
controls, suggesting a  novel role for CD40L  in the  estab- 
lishment and/or maintenance of CD8 + CTL memory. 
Materials and Methods 
Mice.  CD40L-deficient mice were initially constructed as de- 
scribed by Xu et al. (16). The animals used in this study were ob- 
tained by mating mice homozygous for the  CD40L  mutation; 
Southern blot analysis  of DNA derived from tail biopsies, per- 
formed as described by Xu et al.  (16),  was used to confirm ho- 
mozygosity in offspring.  Mice with wild-type CD40L expression 
were bred in parallel with the CD40L-deficient animals for use as 
controls in all experiments. C57L mice and C57BL/6 mice used 
as recipients in adoptive transfer experiments were obtained from 
Jackson Laboratories (Bar Harbor, ME)  and the closed breeding 
colony of The Scripps Research Institute (La Jolla, CA), respec- 
tively. 
Viruses: Preparation of Stocks,  Concentration,  and Titration by Plaque 
Assay.  Viruses  used  were  (a)  the  Armstrong  53b  strain  of 
LCMV, a clone triple plaque-purified from ARM CA 1371 (25); 
(b)  the Mudd-Summers strain of the  Indiana serotype of VSV, 
originally obtained from Dr. J.  Holland (UCSD,  La Jolla, CA); 
and (c) Pichinde virus strain AN3739 (26) obtained from Dr. M.J. 
Buchmeier (The Scripps Research Institute, LaJolla, CA). Stocks 
of each of these viruses were prepared by growth in baby hamster 
kidney cells. Virus stocks were free ofmycoplasma contamination 
as judged by Hoechst staining of cells growing in antibiotic-free 
medium at 48 h after virus infection. 
For use in coating plates, LCMV and PV were concentrated 
and partly purified from the culture fluid of infected cells by pre- 
cipitation with 6.5% polyethylene glycol followed by centrifuga- 
tion at 35,000  rpm in a Beckman SW41  rotor for 75  min on a 
discontinuous renografin gradient (27, 28). VSV was enriched by 
pelleting culture fluids from infected cells and then banding them 
on a 5-40% continuous sucrose gradient (29). 
The  titres of virus stocks,  concentrated preparations of virus, 
and also viral titres in the sera and tissues of infected mice were de- 
termined by plaque assay on Veto cells as previously described (25). 
Infection of Mice and In ~vo Depletion of CD4 + T Cells.  Mice were 
infected as adults (at least 8 wk old) by intraperitoneal (i.p.) inoc- 
ulation with 2 ￿  105 plaque forming units (pfu) of either LCMV or 
PV, or by intravenous (i.v.) inoculation with 5 ￿  10  s PFU of VSV. 
In some experiments mice were depleted of CD4 + T  cells in 
vivo by treatment with the anti-CD4 rat monoclonal antibody 
YTS  191.1  (30).  The antibody was partially purified from ascites 
by ammonium sulfate  precipitation, dialyzed against phosphate- 
buffered saline (PBS),  and adjusted to 10 mg/ml. Mice were in- 
oculated i.v. with  1 mg of antibody on days -1,  +3,  and  +7, 
relative to the time of virus infection (day 0).  The  efficiency of 
depletion ofCD4 § T cells was checked by fluorescence-activated 
cell sorter (FACS  |  analysis of  peripheral blood mononuclear cells 
obtained by eye-bleeding mice just before administration of the 
third dose ofanti-CD4 antibody on day seven after infection, and 
was >99%. 
Assays for Virus-specific CTL Activity.  Virus-specific CTL activ- 
ity was quantitated in vitro in standard chromium-51  (SlCr) re- 
lease assays as described by Byrne and Oldstone (18).  In assays to 
measure primary CTL  activity, effector cells  were  erythrocyte- 
depleted splenocyte suspensions from  mice infected 7  d  previ- 
ously with LCMV, PV,  or VSV. Target cells were SlCr-labeled 
fibroblast cell lines MC57  (H-2  b i.e., syngeneic to the  CD40L- 
deficient  mice)  and  Balb  C1  7  (H-2  a  i.e.,  allogeneic  to  the 
CD40L-deficient mice)  either uninfected,  infected 48  h  before 
51Cr-labeling with  LCMV  or PV  at a  multiplicity of infection 
(moi) of 3 PFU per cell, or infected with VSV at a moi of 100 
PFU per cell immediately before SlCr-labeling so that they were 
used in the assay 2-3 h after infection. Target cells were plated at 
104/well, and effectors added to give effector/target (E:T) ratios 
between 100:1  and 12.5:1.  All variables were set up in triplicate. 
The  assay time was 5  h  for the detection of arenavirus-specific 
CTL activity, and 6 h for VSV. Results are expressed as the per- 
cent specific 51Cr release, calculated as  100X  (experimental re- 
lease  -  spontaneous release)/(maximum release  -  spontaneous 
release). 
LCMV-specific memory CTL activity was assessed by two dif- 
ferent methods. In the first, splenocytes from mice infected with 
LCMV ~-'2 mo previously were restimulated in vitro as described 
by Byrne and Oldstone (18),  then tested for cytolytic activity in 
an in vitro 51Cr-release  assay. Target cells were SlCr-labeled fi- 
broblast cell lines either uninfected or infected with  LCMV  as 
used to test primary LCMV-specific CTL activity, or infected 10 h 
before 51Cr-labeling at a moi of 3 PFU per cell with recombinant 
vaccinia  viruses  (VV)  obtained  from  Dr.  J.L.  Whitton  (The 
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rein  (VVNP)  (31),  full-length glycoprotein  precursor  (VVGP) 
(Dr. J.  Lindsay Whitton, unpubhshed observation), glycoprotein 
1  H-2  b  CTL  epitope  (VVMG  3,  referred  to  in  this  paper  as 
VVGP1)  (32),  or  glycoprotein 2  H-2  b CTL  epitope  (Vvg,  re- 
ferred to in this paper as VVGP2) (33)  of LCMV, or [3-galactosi- 
dase only (VVSCll) (31) as a control. 
Alternatively splenocytes were adoptively transferred (without 
in vitro restimulation) into syngeneic recipient mice persistently 
infected with LCMV to determine whether they could mediate 
viral clearance in vivo. C57BL/6 mice persistently infected with 
LCMV were produced by inoculating neonatal mice (within 48 h 
of birth) with  103 PFU of LCMV Armstrong intracranially (ic); 
persistently infected animals were used as adoptive transfer recipi- 
ents  when  2-4  mo  old.  Recipient  mice  were  irradiated  (300 
rads),  then the following day were inoculated i.p. with 4  ￿  107 
donor splenocytes, and subsequent virus clearance was assessed by 
measuring serum virus titres 14 d later. 
Enzyme Linked Immunosorbent Assays (ELISAs) for Measurement 
of Antiviral Antibody Levels.  Antiviral antibody levels were deter- 
mined by ELISA,  using a  method  based  on  that  described by 
Ahmed et al. (34).  Briefly, Falcon Microtest III 96-well flat-bot- 
tomed plates (Becton Dickinson and Co., Oxnard, CA) were coated 
overnight with partly purified LCMV, PV or VSV at 5 mg/ml in 
PBS. After a blocking step, primary antibodies were added: four- 
fold dilutions of each serum sample from  1/25 to  1/25,600,000 
were  tested.  Antibody binding was  detected using as secondary 
antibodies  horseradish  peroxidase-conjugated  anti-mouse  IgM 
(used at  1/2,000),  anti-mouse IgG F  c  (used at  1/50,000),  anti- 
mouse IgG1  (used at 1/1,000), and anti-mouse IgG2a (also used 
at 1/1,000), all purchased from Cappel Research Products (Orga- 
non Teknika Corporation, Durham, NC), followed by an ortho- 
phenyldiamine-containing  substrate. Plates were read at 492 nm 
using a Titertek Multiskan MCC/340 ELISA reader (Flow Labo- 
ratories, Inc., Santa Barbara, CA). Endpoint titres of virus-bind- 
ing serum antibodies were determined as the last serum dilution 
giving an absorbance at 492 nm more than three standard devia- 
tions above the mean value of eight negative control wells on that 
plate. In some experiments results are expressed as endpoint titres 
of virus-specific serum antibody, i.e., virus-binding serum anti- 
body titre at a particular time post-infection minus the titre of vi- 
rus-binding antibody  (if any)  in the  pre-infection bleed serum 
sample from the same mouse. 
The antigen specificity of the ELISA technique was shown by 
the finding that unlike post-infection sera from VSV-inoculated 
mice, post-infection sera from arenavirus-inoculated  mice did not 
show any increase over pre-immune levels in binding to VSV- 
coated  plates  in this  assay,  and vice-versa. To  demonstrate the 
specificity of the second antibodies used for the appropriate mouse 
immunoglobulin classes/subclasses,  an ELISA was  performed in 
which plates were  coated with purified mouse IgM,  IgG1, and 
IgG2a standards  (Southern Biotechnology Associates,  Inc., Bir- 
mingham, AL)  at  concentrations from  10-0.01  mg/ml in PBS, 
and the ability of the four different second antibodies (at the con- 
centrations at which they were routinely used in the ELISAs for 
virus-specific antibody detection) to bind to these immunoglobu- 
lin standards was  measured.  Most  importantly, this  experiment 
demonstrated that there was a complete absence of cross-reactiv- 
ity of the anti-total IgG and the two lgG subclass-specific second 
antibodies on IgM. 
ELISPOT Assay  for Quantitation of Antiviral Antibody Secreting 
Cells (AS(?,).  LCMV- and VSV-specific ASC in the spleen and 
bone marrow of infected mice were quantitated by an ELISPOT 
method based on that detailed in Slifka et al. (35).  Briefly, nitro- 
ceUulose-bottomed 96-well Multiscreen HA filtration plates (Mil- 
hpore Corporation, San Francisco, CA) were coated overnight at 
4~  with 50  I~l/well of concentrated, partly purified LCMV or 
VSV, or bovine serum albumin (BSA)  at 10 mg/ml in PBS, then 
were washed and non-specific binding sites were blocked. Eryth- 
rocyte-depleted single cell  suspensions were  prepared  from  the 
spleen and bone marrow (from one femur) of LCMV- and VSV- 
infected mice, and resuspended in RPMI medium containing 7% 
FBS at  107 ceUs/ml. Threefold dilutions of the cells were added 
to  the plates in 100-l~l vol/well. Plates were  then incubated at 
37~  in a humid atmosphere with 5% CO2 for 4-5 h, after which 
they were washed and specific antibody bound to the plates was 
detected by successive incubations with a biotinylated mouse anti- 
mouse IgG2a  b antibody (PharMingen, San Diego, CA), horserad- 
ish peroxidase-conjugated avidin D  (Vector Laboratories, Burlin- 
game,  CA),  and a  3-amino-9-ethylcarbazole (AEC)-containing 
substrate. Spots where antibody was present were enumerated us- 
ing a large magnifying glass. The antigen specificity of this tech- 
nique was  demonstrated by the  finding that no spots were  ob- 
served  when  cells  from  LCMV-infected  mice  were  tested  on 
VSV-coated plates, and vice-versa; also  no spots were  observed 
when cells  from mice infected with either virus were  tested on 
BSA-coated plates. 
Immunocytochemical Analysis of Germinal Centers.  Spleens  were 
removed from uninfected mice and mice infected with VSV 10 d 
previously (the peak time of the germinal center reaction)~ em- 
bedded in Tissue-Tek OCT compound (Miles Diagnostics Divi- 
sion, Elkhart, IN), snap frozen in isopentane-dry ice, and stored at 
-20~  Immunohistochemical staining was performed on 10-p,m 
cryostat sections using a method based on that described by Bor- 
row et al. (36). Briefly, sections were fixed for 10 min with acetone 
at 4~  rinsed in PBS, blocked with avidin and biotin solutions 
(Vector Laboratories, Inc., Burlingame, CA), then incubated with 
biotinylated peanut  agglutinin lectin  (PNA)  (Biomeda  Corp., 
Foster City, CA; 2 mg/ml stock solution used at a 1/1,000 dilu- 
tion) or PBS only as a control for 1 h at room temperature. After 
washing in PBS, slides were incubated for a further hour at room 
temperature with peroxidase-conjugated streptavidin (Jackson  Im- 
munoresearch Laboratories, Inc., West Grove, PA; used at a 1/500 
dilution in PBS), washed again in PBS, and then staining was de- 
tected  with  diaminobenzidine (DAB)  as  a  chromagen.  Finally, 
sections were  counterstained with Mayer's hematoxylin (Sigma, 
St.  Louis, MO)  and mounted in Aqua-Mount (Lerner Laborato- 
ries, Pittsburgh, PA). 
Adoptive Transfer Experiments for  Analysis of B  Cell Memory. 
To determine whether memory B cells were developed following 
virus  infection of CD40L-deficient  mice,  erythrocyte-depleted 
splenocyte suspensions were prepared from CD40L-deficient and 
wild-type  mice  infected  3  to  4  mo  previously with  VSV  or 
LCMV, and also  from uninfected wild-type mice, all of which 
were  on the  CS7BL/6  background  (H-2  b,  Ighb),  and 5  X  106 
cells/mouse were adoptively transferred into irradiated (600 rads) 
C57L recipients (H-2  b,  Igh"),  which had been primed with the" 
homologous virus 6  wk previously. Recipient mice were  chal- 
lenged  with  the  appropriate  virus  at  the  time  of transfer.  7, 
10, and 14 d later, the recipient mice were  eye-bled, and serum 
titres of antiviral IgG2a  b assessed by ELISA employing a biotiny- 
lated IgG2ab-specific secondary antibody (PharMingen; used at a 
1/5,000 dilution in PBS plus 10% FBS) followed by peroxidase- 
coupled streptavidin (Jackson Irnmunoresearch Laboratories, Inc., 
West  Grove,  PA;  used at  a  1/2,000  dilution) to  detect  IgG2a  b 
binding. 
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Analysis  of Primary CTL and Antibody  Responses in  Virus- 
infected CD4OL-deficient Mice.  To investigate potential roles 
CD40L may play in the functioning of the immune system 
in vivo, the immune response mounted following virus in- 
fection  by  CD40L-deficient  mice,  which  were  generated 
by gene targeting (16), was examined. 
In initial experiments the primary cell-mediated and hu- 
moral immune  responses made by CD40L-deficient mice 
infected  with  VSV,  LCMV,  and  PV  were  compared  to 
those mounted by wild-type animals. Groups of six to eight 
CD40L-deficient  and  wild-type mice  were  infected with 
each virus. Several animals from each group were sacrificed 
7  d  after infection, and the primary antiviral CTL  activity 
mediated by splenocytes from  individual mice  was  deter- 
mined  by  51Cr  release  assay.  CD40L-deficient  mice  in- 
fected with  VSV,  LCMV,  or PV  mounted  virus-specific, 
major histocompatibility complex  (MHC)-restricted  CTL 
responses  that  were  indistinguishable from  those  of wild- 
type mice  (Table  1  and  data  not  shown),  indicating that 
CD40L  is not  essential for the induction of primary CTL 
responses following virus infection. This result is consistent 
with the fact that CD40L is absent or expressed at only very 
low levels on the majority ofCD8 + T  cells (1, 3, 4, 6, 7). 
The remaining mice in each group were eye-bled at dif- 
ferent  times in  the  2-too period after virus infection,  and 
their  serum  titres  of virus-specific IgM,  total  IgG,  IgG1, 
and IgG2a antibody were determined by ELISA using ap- 
propriate isotype-specific peroxidase-conjugated secondary 
antibodies. Fig. 1 a shows the ELISA results obtained in an 
assay measuring the levels of virus-binding total IgG in pre- 
infection and  day  14 post-infection serum samples from  a 
representative CD40L-deficient and wild-type mouse,  and 
illustrates  the  difference  in  the  endpoint  titres  of virus- 
binding serum antibody in the two day 14 samples. Fig. 1 b 
summarizes the mean endpoint titres of virus-specific serum 
IgM, total IgG, IgG1, and IgG2a in groups of CD40L-defi- 
cient and wild-type mice at different times after infection 
with VSV or LCMV.  It can be seen that CD40L-deficient 
mice produced lower levels of virus-specific antibody of the 
IgM isotype than wild-type animals. Surprisingly, as well as 
producing virus-specific IgM, infected CD40L-deficient mice 
also made an antiviral IgG response, although again this was 
Table  1.  Primary  CTL Responses Mounted by CD4OL-deficient and Wild-type Mice after Infection with Different Viruses* 
Source of effector cells 
Target cells 
H-2  b uninf  H-2  b +  VSV  H-2  d uninf  H-2  a +  VSV 
VSV-in~ctedwild-typemice 
W1  0/0  59/52  2/0  0/2 
W2  12/4  65/49  ND/1  ND/4 
W3  0/0  48/39  ND/0  0/0 
VSV-in~cted CD40L-deficientmice 
D1  3/0  59/32  5/0  2/0 
D2  9/7  49/34  5/0  10/0 
D3  13/6  57/37  ND/4  8/0 
Target cells 
H-2  b uninf  H-2  b +  LCMV  H-2  a uninf  H-2  d +  LCMV 
LCMV-in~ctedwild-typemice 
W4  7/0  77/49  8/4  13/6 
W5  1/0  50/39  1/0  16/1 
W6  0/0  71/57  3/2  5/5 
LCMV-in~cted CD40L-deficientmice 
D4  2/0  81/67  3/2  15/9 
D5  5/2  62/47  2/1  13/8 
D6  1/1  78/78  10/5  13/15 
*  The ability of splenocytes from CD40L-deficient and wild-type mice infected 7 d previously with VSV or LCMV to mediate virus-specific MHC- 
restricted CTL lysis was tested by in vitro 51Cr-release assays. Target cells  were MHC-matched (H-2  b) or mismatched (H-2  a) fibroblast lines either 
uninfected or infected with VSV or LCMV. The results shown are the mean (of triplicate wells) percent specific 51Cr-release (calculated as described 
in Materials and Methods) mediated by effector splenocytes from individual CD40L-deficient  (D1-6) or wild-type (W1-6) mice at E:T ratios of 100: 
1/50:1 (experiment with VSV) or 25:1/12.5:1  (experiment with LCMV). The variance was always <10%. 
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wild-type animals. In addition, while wild-type mice pro- 
duced antiviral IgG of both the IgG1  and IgG2a isotypes, 
infected CD40L-deficient mice did not produce a signifi- 
cant  amount  of virus-specific  IgG1.  Further,  whereas  in 
wild-type mice the serum titres of virus-specific IgG were 
sustained at two months post-infection at similar levels to 
those present 7-10  d  after infection, in  CD40L-deficient 
mice a 1-2 log decrease in serum IgG titres occurred over 
this  time period.  Very similar results were  obtained with 
PV-infected mice (not shown). Thus while CD40L-medi- 
ated interactions are clearly involved in the generation of 
the primary humoral immune response following virus in- 
fection, and are essential  for the production of antiviral an- 
tibody of the IgG1  isotype, modest levels of virus-specific 
IgM and a short-lived IgG response of the IgG2a isotype 
are generated in virus-infected mice by a CD40L-indepen- 
dent mechanism. 
Mechanism of lgG Production in  Virus-infected CD4OL-defi- 
cient Mice.  A further series of experiments investigated how 
antibody of the  IgG isotype was  being produced in  the 
absence of CD40L-mediated interactions. Although CD40- 
CD40L interactions are known normally to be required for 
thymus-dependent humoral immune responses (1, 2, 5,  7, 
9, 11), there are reports ofCD4 § T  cells stimulating B cells 
to undergo activation and class switching by non-CD40L- 
mediated mechanisms including via membrane TNF-cx or by 
CD2-CD58-dependent pathways (37-40). In addition, an- 
tibody  production  to  T-independent  antigens  has  been 
shown not to involve CD40L-mediated interactions (5, 10, 
11, 16, 17). Whether the antiviral IgG production observed in 
infected CD40L-deficient mice was occurring by some CD4 + 
T  cell-dependent mechanism or alternatively by a CD4 + T 
cell-independent pathway was  thus determined. CD4 + T 
lymphocytes  were  depleted  from  CD40L-deficient  and 
wild-type mice using a CD4-specific monoclonal antibody 
(30),  then these and undepleted control animals were in- 
fected with VSV or LCMV, and the serum titres of virus- 
specific  IgM,  total  IgG,  IgG1,  and  IgG2a  measured  by 
ELISA on  days  7  and  10  post-infection.  The results  ob- 
tained in the experiment using VSV are shown in Fig.  2; 
similar data were obtained with LCMV-infected mice (not 
shown).  The antiviral  IgG response mounted by CD4 + 
T  cell-depleted CD40L-deficient mice was found to be just 
as strong as that made by CD40L-deficient mice from which 
the CD4 + T  cells were not depleted, indicating that the vi- 
rus-specific antibody production in CD40L-deficient mice 
was  occurring by a  CD4 +  T  cell-independent pathway. 
Further, the level of antiviral IgG production in wild-type 
mice depleted of CD4 § T  cells before virus infection was 
reduced compared to that made by non-depleted wild-type 
animals to a similar level to that observed in CD40L-defi- 
cient animals,  and again as in CD40L-deficient animals, al- 
though  virus-specific  IgG2a  was  produced  by  CD4 +  T 
cell-depleted wild-type mice, almost no IgG1  production 
was  observed.  This  demonstrates  that  in  virus-infected 
wild-type mice too, there is a CD4 + T  cell-independent 
component  to  the  antiviral  antibody  response,  although 
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this is supplemented by a CD4 § T  cell-dependent compo- 
nent that is necessary for high titres of IgG to be produced, 
and for class switching to IgG1 to occur. 
These results are in agreement with previous reports that 
the humoral immune response to VSV has  a T  cell-inde- 
pendent component (41, 42) in addition to neutralizing IgG 
being produced by a TH-dependent mechanism (43). Thy- 
mus-independent antigens fall into two classes: type I anti- 
gens, which are B cell mitogens and cause polyclonal B cell 
activation; and type II antigens which have no intrinsic B cell 
stimulating activity, but possess highly repetitive structures 
and stimulate specific mature B  cells by extensively cross- 
linking their surface immunoglobulin. There is some con- 
troversy as to whether VSV glycoproteins have mitogenic 
activity (44, 45); however as virions consist of highly orga- 
nized arrays  of viral proteins, they are certainly able to act 
as type II thymus-independent antigens  (45).  The fact that 
production  of cytokines such  as  interferon-~/  (IFN-~/)  is 
stimulated  at  high  levels  after  virus  infection  likely  also 
played a part in the antibody generation observed in CD40L- 
deficient mice, as cytokines are potent regulators of B  cell 
responses to thymus-independent antigens. IFN-',/, for ex- 
ample, regulates both B cell maturation to Ig secretion and 
Ig class switehing in immune responses to thymus-indepen- 
dent antigens (46, 47). Treatment of CD40L-deficient mice 
with an antibody that blocks the activity of IFN-~/ (48) in 
fact resulted in a slight increase in the level of virus-specific 
IgG  produced  following infection  with  VSV  or  LCMV 
(data  not shown),  suggesting that IFN-~/ is probably only 
one of a network of cytokines that regulates antibody re- 
sponses to type II thymus-independent viral antigens. 
Control  of Acute  Virus  Infection in  CD4OL-deficient  Mice. 
Whether the primary humoral and cell-mediated immune 
responses mounted by CD40L-deficient mice were sufficient 
to  confer protection against  acute  infection with  LCMV 
and VSV was also investigated. Groups of 15 CD40L-defi- 
cient and  wild-type mice were  infected with  each virus, 
and three animals from each group were killed 1, 3,  5, 7, 
and 10 d post-infection and infectious virus titres in the se- 
rum,  spleen, and liver determined by plaque assay. Fig.  3 
shows the LCMV titres in the spleen and liver of CD40L- 
deficient and wild-type mice over time post-infection: the 
CD40L-deficient mice cleared infectious virus from these 
tissues (and also the serum, data not shown) with similar ki- 
netics to the wild-type animals.  As LCMV clearance is pri- 
marily mediated by virus-specific CD8 + CTL (18-21), this 
finding was  consistent with the  data  in  Table  1 showing 
that as measured by in vitro SlCr-release assay, the primary 
CTL response mounted by CD40L-deficient mice is equi- 
valent to that mounted by wild-type animals. 
After infection with VSV,  mice exhibit a natural resis- 
tance to viral replication in the periphery, which is medi- 
ated by IFN-cx/13  (49,  50).  In keeping with such an innate 
resistance  mechanism,  although  low viral  titres were  ob- 
served in the  spleen and serum of some CD40L-deficient 
and  wild-type mice  on  the  first  day after infection with 
VSV (not shown), infectious virus was  undetectable in the 
periphery of both groups of mice thereafter. Interestingly, however,  during  the  course  of all  the  experiments  per- 
formed with VSV-infected CD40L-deficient mice and wild- 
type controls, several CD40L-deficient mice were found to 
die  8-12  d  after  infection with  VSV,  whereas  no  similar 
deaths  occurred in  VSV-infected  wild-type  control  mice. 
The deaths  of the  CD40L-deficient mice were likely due 
to VSV-induced meningoencephalitis  (51). As the antiviral 
antibody  response  normally  contributes  to  protection  in 
VSV-infected  mice  (23,  24),  these  deaths  may  have  oc- 
curred  as  a  consequence  of the  reduced  titres  of antiviral 
antibodies produced by the CD40L-deficient animals  (Fig. 
1  b);  central  nervous  system  (CNS)  antibody  levels  may 
have been insufficient to mediate  control of virus replica- 
tion in the brain. 
Analysis  of Long-term  Production of Antiviral  Antibody  by 
CD4OL-deficient Mice.  Results shown in Fig. 1 illustrate that 
although CD40L-deficient mice did mount a humoral im- 
mune response after infection with VSV or LCMV, serum 
titres  of virus-specific  IgG were not sustained,  but waned 
over the 2-mo period after infection. By contrast, serum ti- 
tres of antiviral IgG in similarly infected wild-type mice re- 
mained high over this time period.  It has been shown that 
whereas at early times after infection of wild-type mice with 
viruses such as LCMV, large numbers of cells  secreting vi- 
rus-specific antibody are found in the spleen, at later times 
post-infection  antiviral  plasma  cell  numbers  in  the  spleen 
dechne,  and a population of virus-specific plasma cells ap- 
pears in the bone marrow that constitutes the major source 
of long-term antibody production (35). Whether the wan- 
ing  titres  of  antiviral  antibody  in  the  serum  of  virus- 
infected  CD40L-deficient  mice  correlated  with  a  lack  of 
population of the bone marrow with virus-specific ASC in 
these  mice  was  thus  investigated.  CD40L-deficient  and 
wild-type mice were infected with either VSV or LCMV, 
and the number of cells in the spleen and bone marrow se- 
creting virus-specific  IgG2a was  quantitated  by ELISPOT 
assay on days 14 and 64 post-infection. The results in Table 
2 show that 14 d post-infection the number of cells actively 
secreting  virus-specific  IgG2a  in  CD40L-deficient  mice 
was ~20-fold lower after LCMV infection,  and three-  to 
eightfold lower after VSV infection than in infected wild- 
type mice, consistent with the relative serum titres of virus- 
specific IgG2a shown in Fig. 1 b. Interestingly, however, in 
CD40L-deficient mice just  as in wild-type mice,  although 
the majority of the antiviral plasma cells  were found in the 
spleen at this timepoint,  some ASC could also be detected 
in  the  bone  marrow.  The  ratio  of spleen:  bone  marrow 
ASC in LCMV-infected CD40L-deficient mice was approx- 
imately equal to that in wild-type animals, while following 
VSV infection  it  was  slightly  higher  in  the  CD40L-defi- 
cient  mice.  However,  ASC  did  not  persist  in  the  bone 
marrow of CD40L-deficient mice: by 2 mo post-infection, 
virus-specific IgG2a-secreting cells could no longer be de- 
tected in either the spleen  or the bone marrow of LCMV 
or  VSV-infected  CD40L-deficient  animals  (Table  2).  By 
contrast, in similarly infected wild-type mice, although the 
number ofantiviral plasma cells in the spleen had decreased 
~'-'50-fold, virus-specific ASC numbers in the bone marrow 
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Figure  1.  Comparison of the antiviral antibody response mounted by 
CD40L-deficient and wild-type mice following infection with VSV or 
LCMV. Groups of three to eight CD40L-deficient and wild-type mice 
were infected with VSV or LCMV, and the serum titres of virus-binding 
antibody of  the lgM, total IgG, IgG1, and IgG2a isotypes in prebleed and 
serum samples obtained at the indicated times post-infection were deter- 
mined by ELISA as detailed in Materials and Methods. (a) ELISA results 
obtained when prebleed (squares) and day 14 post-infection (triangles)  se- 
rum samples from a representative CD40L-deficient (open symbols) and 
wild-type (filled  symbols) mouse infected with VSV were tested for VSV- 
binding total IgG. The endpoint ELISA  titres of  VSV-binding antibody in 
the two day fourteen samples (i.e., last serum dilution which gave an ab- 
sorbance value at 492 nm more than three standard deviations above the 
mean value of the negative control wells on the plate on which it was 
tested) axe indicated by the arrows. (b) Mean log  m reciprocal endpoint ti- 
tres of virus-specific serum antibody of the IgM, total IgG, IgG1, and 
lgG2a isotypes in groups of CD40L-deficient (open bars) and wild-type 
(shaded bars) mice at the times shown following infection with VSV or 
LCMV. The vertical lines indicate one standard error above and below 
the mean titre for each group of animals. 
remained much more constant at this timepoint  (Table 2). 
These results demonstrate that population of the bone mar- 
row  by  virus-specific  ASC  can  occur  in  the  absence  of 
CD40L-mediated interactions,  but that the ASC generated 
by CD40L-independent mechanisms do not persist in vivo. 
Investigation of Whether Germinal Center Formation and the 
Development of B  Cell Memory  Occur after Virus Infection of 
CD4OL-deficient Mice.  In  normal  mice,  plasma  cell  pre- 
cursors are thought to be generated in germinal centers, re- 
gions which develop transiently within the primary follicles 
of secondary lymphoid organs following antigenic stimula- 
tion where B cells undergo antigen-driven oligoclonal pro- 
liferation, and isotype switching and affinity maturation oc- 
cur (52, 53). Whether the lack of persistence of plasma cells 
producing  virus-specific  antibody  observed  in  CD40L- 
deficient mice correlated with a  defect in germinal  center 
formation after virus infection of these  mice was  thus  in- 
vestigated. CD40L-deficient and wild-type mice were killed 
10 d after infection with VSV, the peak time of the germi- 
nal center reaction, and their spleens were analyzed immu- 
nocytochemically for PNA binding,  characteristic  for ger- 
minal  center  B  cells  (Fig.  4).  Although  large  numbers  of 
germinal centers were seen to have formed in the spleen of 
wild-type  mice  after  infection  with  VSV  (compare  the 
staining in Fig. 4  b with a),  no germinal centers were seen 
in the VSV-infected CD40L-deficient mice (Fig. 4 c). This 
result was consistent with the previous finding that CD40L- 
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Figure 2.  Effect  of CD4 + T cell depletion on the antiviral antibody response mounted by CD40L-deficient  and wild-type mice after infection with 
VSV. Groups of three wild-type and CD40L-deficient mice which were either depleted ofCD4 + T cells by treatment with an anti-CD4 monoclonal an- 
tibody, or were undepleted, were infected with 5 ￿  105 PFU VSV iv, and their serum titres of VSV-specific antibody of the IgM, total IgG, IgGl, and 
IgG2a isotypes were determined on days 7 and 10 post-infection by ELISA as detailed in Materials and Methods. The results shown are the mean log10 
reciprocal endpoint titres of VSV-specific serum antibody of each isotype in each group of mice. The bars represent [] undepleted wild-type mice; ￿9 
CD4 + T cell-depleted wild-type mice; [] undepleted CD40L-deficient mice; [] CD4 + T cell-depleted CD40L-deficient mice. The vertical lines indicate 
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Figure  3.  Virus clearance from the spleen and liver of wild-type and 
CD40L-deficient  mice  after  infection  with  LCMV.  Wild-type  and 
CD40L-deficient mice were infected with 2 X 105 PFU LCMV ip, and 1, 
3, 5, 7, and 10 d later three mice from each group were sacrificed and the 
deficient mice do not form germinal centers after immuni- 
zation  with  inert  antigens  such  as  sheep  red  blood  cells 
(16), as well as with the observation that HIM patients lack 
detectable germinal centers (10). 
The generation of antigen-specific memory B  cell clones 
is another process that is thought to occur within germinal 
centers (53),  and which has been shown to be inhibited in 
mice  treated  with  antibody specific  for  CD40L  (12)  or  a 
soluble CD40 fusion protein that blocks CD40L-CD40  in- 
teraction  (13).  Engagement of CD40  by CD40L  prevents 
the apoptosis of germinal center B  cells, likely via bd-x up- 
regulation, thus contributing to antigen-driven selection of 
memory B  cells (54,  55).  Whether  CD40L-deficient mice 
thus failed to develop memory B  cells after virus infection 
was investigated in adoptive  transfer experiments.  Spleno- 
cytes  from  CD40L-deficient  and wild-type  mice  infected 
3-4  mo  previously with  VSV  or  LCMV,  or  from  unin- 
fected mice, all on the C57BL/6  background (H-2  b,  Igh  b) 
were  adoptively transferred  into C57L  (H-2  b,  IgH  a)  mice 
which had been immunized with the homologous virus 6 wk 
previously,  and  would  thus  provide  syngeneic  memory 
helper T  cells. The recipient mice were reinoculated with 
the  appropriate  virus at the  time  of adoptive  transfer;  and 
the  levels  of virus-specific  IgG2a  antibody  of the  donor 
(Igh  b)  type in the  recipient sera were  measured by ELISA 
7,  10, and 14 d  post-transfer. As shown in Fig. 5, although 
increasing titres  of virus-binding IgG2a  b were  observed in 
the sera of mice which received cells from wild-type mice 
titres of infectious LCMV in the spleen (a) and liver (b) of individual ani- 
rnals were determined by plaque assay on Vero cells. Each bar represents 
the virus titre  (log10 pfu/g tissue) in the spleen or liver of an individual 
wild-type (shaded bars) or CD40L-deficient  (open bars) mouse killed at the 
indicated time post-infection. Where no bar is shown, virus was not de- 
tected by the plaque assay (the sensitivity of which was "200 pfu/g tissue) 
in that tissue sample. 
2136  Role of the CD40 Ligand in Antiviral Immunity Table 2.  Number  of Virus-specific IgG2a-secreting Cells  per 106 
Leukocytes in the Spleen and Bone Marrow of CD4OL-deficient and 
Wild-type Mice on Days 14 and 64 Post-infection 
ASC/106 cells in: 
Mice  Spleen  Bone marrow 
WT, day 14 after LCMV  570 +  163  32  +  20 
D, day 14 after LCMV  29 +- 5  2 +- 1 
WT, day 64 after LCMV  16  +  7  31  •  5 
D, day 64 after LCMV  0  •  0  0  +- 0 
WT, day 14 after VSV  1375  +  275  176  +  33 
D, day 14 after VSV  583  •  87  22 +  6 
WT, day 64 after VSV  27  +  5  53  +  10 
D, day 64 after VSV  0  -+ 0  0  +  0 
The number of leucocytes in the spleen and bone marrow of CD40L- 
deficient (D) and wild-type (IV/) mice infected 14 or 64 d previously 
with LCMV or VSV which were actively secreting IgG2a antibody spe- 
cific for the infecting virus was quantitated by ELISPOT assay, as de- 
scribed in Materials and Methods.  The results shown  are the mean  -+ 
standard error number of ASC per 106 leucocytes (ASC/106 cells) in the 
spleen and bone marrow of groups of 3-5 mice. 
previously infected with VSV over the  14-d period exam- 
ined, the level of virus-reactive IgG2a  b detected in the sera 
of mice that received cells from CD40L-deficient mice pre- 
viously infected with this virus was  consistently very low, 
comparable to that found in the sera of mice that received 
cells from previously untreated donors. Very similar results 
were obtained using LCMV (not shown). These results dem- 
onstrate that  although virus-specific memory B  cells were 
present  in  the  spleen of wild-type mice  infected 3-4  mo 
previously with VSV or LCMV, similarly-infected CD40L- 
deficient mice did not appear to have  developed memory 
B  cells specific for their previous virus infection. Although 
B  cell memory was not developed following virus infection 
of CD40L-deficient mice, the B  cells in these animals were 
also  not  tolerized  to  the  infecting  virus,  as  comparable 
(low) levels of virus-specific IgM  b were detected in the se- 
rum of recipients of cells from all three types of donor mice 
(virus-infected wild-type or CD40L-deficient mice, or pre- 
viously uninfected mice) (data not shown). 
In summary, after infection with viruses such as VSV and 
LCMV,  CD40L-deficient mice mount  a  primary antiviral 
antibody response (Fig.  1) by a  CD4 +  T  cell-independent 
mechanism  (Fig. 2), likely caused by virion proteins cross- 
linking the membrane immunoglobulm of specific B  cells suf- 
ficiently to directly trigger them to produce antiviral antibody 
of the IgM and IgG2a isotypes. However, in the absence of 
CD40L-mediated  interactions,  germinal  center  formation 
does not  occur  (Fig. 4),  and processes which  are believed 
normally to  occur within germinal centers: further isotype 
switching,  generation of long-lived plasma cells, and pro- 
duction  of antigen-specific memory  B  cells,  do  not  take 
place (Fig.  1,  Table 2,  Fig. 5).  These results in in vivo in- 
fection systems are consistent with conclusions from previ- 
ous  studies  of the  in  vivo role  of CD40L-CD40  interac- 
tions  in  the  generation  of humoral  immune  responses  to 
inert antigens  (5,  11-13,  16,  17).  A  number  of interesting 
questions  arise  from  these  findings.  For  example,  how 
many CD40L-mediated interactions normally occur in each 
of the processes that fail to  take place in CD40L-deficient 
mice, and between what cell types? Does the lack of an ini- 
tial CD40L-mediated interaction between B  cells and CD4 + 
T  cells account for the failure of germinal center formation, 
which in turn results in B  cells not being in a suitable mi- 
croenvironment  to  undergo  isotype switching  and  devel- 
opment into long-lived ASC and memory B  cells; or are a 
series of CD40L-mediated  interactions,  perhaps  involving 
B  cells, CD4 + T  cells, follicular dendritic cells in the spleen 
and lymph nodes, and some cell type in the bone marrow 
involved in these processes? The latter seems likely in view 
of the large number of different cell types on which expres- 
sion  of CD40  or its ligand has been  documented  (8,  14), 
but precise definition of the steps involved requires further 
studies. 
Study of CTL Memory in CD4OL-defident Mice.  A  final se- 
ries  of experiments  examined  memory  CTL  activity  in 
CD40L-deficient mice which had previously undergone an 
acute infection with LCMV. LCMV-specific memory CTL 
activity was  initially assessed by  restimulating  splenocytes 
Figure 4.  Germinal center formation occurs in wild-type but not CD40L-deficient mice after infection with VSV. Spleens were cryopreserved from 
uninfected wild-type mice (a) and wild-type (b) and CD40L-deficient (c) mice infected 10 d previously  with 5 ￿  105 pfu VSV iv. 10-1*m  cryosections  were 
stained as described in Materials and Methods by incubation with biotinylated PNA followed by peroxidase-conjugated  streptavidin, and staining was de- 
tected with DAB as a chromagen, which gives a brown product. Hematoxylin was used as a counterstain. Germinal centers are readily apparent in the 
spleen of wild-type mice infected with VSV (b), but not similarly-infected  CD40L-deficient animals (c). Bar, 333 Ixm. 
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Figure  5.  Adoptive  transfer 
experiment  comparing  B  cell 
memory  in  wild-type  and 
CD40L-deficient mice after  in- 
fection  with  VSV. Splenocytes 
from  uninfected  wild-type mice 
and  wild-type  and  CD40L-defi- 
cient  mice  which  were  infected 
3-4 mo previously with VSV all 
on the C57BL/6 background  (H- 
2  b,  lghb), were adoptively  trans- 
ferred  into  wild-type C57L  re- 
cipients  (H-2  b,  Igh  ~)  that  had 
been  primed  with  VSV  6  wk 
previously. Recipient mice were 
challenged with VSV at the time 
of transfer, At the indicated times 
after the adoptive transfer, the ti- 
tres of antiviral IgG2a of the do- 
nor type  (IgG2a  b) in  the recipi- 
ent  sera were  detemfined  by 
EL[SA  as  detailed  in  Materials 
and Methods.  The bars represent 
the logu) reciprocal  endpoint ti- 
tres of antiviral IgG2a  h in the se- 
rum  of individual  mice  which 
received cells from [] uninfected 
donors,  []  virus-infected  wild- 
type donors, and [] virus-infected 
CD40L-deficient mice. 
from  CD40L-deficient  and  wild-type  mice infected  2  mo 
previously with  LCMV  for  6  d  in  vitro,  and  then  testing 
their ability to mediate virus-specific MHC-restricted CTL 
lysis  in  a  51Cr-release  assay.  Results  from  a  representative 
experiment shown in Table  3  illustrate that  although  sple- 
nocytes  from  CD40L-deficient  mice  did  mediate  MHC- 
restricted  CTL  lysis  of LCMV-infected  target  cells,  the 
level of CTL  activity they exhibited was lower than that  of 
splenocytes  from  wild-type  animals.  The  LCMV-specific 
CTL response in H-2  b mice is known to be directed against 
three  epitopes,  one in the viral nucleoprotein  (NP), one in 
glycoprotein 1  (GP1),  and one in glycoprotein 2  (GP2);  of 
these, the NP  epitope is the most dominant  (56).  In accord 
with  the  expected  relative  frequencies  of memory  CTL 
precursors  (CTLp)  for these  three  epitopes,  memory  CTL 
from wild-type  mice lysed  target  cells infected  with  a  re- 
combinant vaccinia virus expressing LCMV  NP  more effi- 
ciently  than  those  infected  with  recombinant  vaccinia  vi- 
ruses expressing LCMV  GP or the GPI  or GP2 H-2  b CTL 
epitopes  (Table  3); similarly while NP-specific CTL  activ- 
ity  could  readily  be  detected  in  CD40L-deficient  mice, 
GP-specific CTL  activity was so low as to be virtually un- 
detectable by this assay (<10%  specific 51Cr release)  (Table 
3).  CD40L-deficient mice did possess  CTLp specific for all 
three  of the known  H-2b-restricted LCMV  CTL  epitopes, 
however, as when splenocytes from CD40L-deficient mice 
Table 3.  Memory CTL Activity in CD4OL-deficient and Wild-type Mice 2 mo after Infection with LCMV, as Measured by an In Vitro SlCr 
Release Assay* 
Target cells 
H2  b 
Source of Effectors  E:T Ratio  Uninf  LCMV  VVNP  VVGP  VVGP1  WGP2 
H-2  d 
LCMV 
Wild-type mice  25:1  2  69  53  41  31  26  3 
CD40L-deficient mice  25:1  0  44  25  8  0  5  1 
"Spenocytes pooled from groups  of CD40L-deficient or wild-type mice infected 2 mo previously with LCMV were restimulated  by in vitro culture 
with irradiated  syngeneic  LCMV-infected peritoneal macrophages  as detailed in Materials and Methods. They were then tested for LCMV-specific 
CTL activity in an in vitro SlCr-release assay. Target cells were MHC-matched (1-I-2  b) or mismatched (1-1-2  d) fibroblast lines either uninfected, in- 
fected with LCMV, or infected with recombinant vaccinia viruses encoding the nucleoprotein (VVNP), full-length glycoprotein precursor (VVGP), 
GP1 H-2 b CTL epitope (VVGPI), or GP2 CTL epitope (VVGP2) of LCMV. The results shown are the mean (of triplicate  wells) percent specific 
SICr-release (calculated as described in Materials and Methods)  mediated by splenocyte cultures at the E:T ratios shown. The variance was always < 10%. 
2138  Role of the CD40 Ligand in Antiviral Immunity were cultured in vitro for a  13-d period before testing in a 
51Cr-release assay, to allow more expansion of virus-specific 
CTL  to occur,  CTL  activity specific for all three epitopes 
could  then  be  detected  in  these  mice  in  addition  to  the 
wild-type animals (not shown). Altogether, the results from 
these  experiments demonstrate  that  although  LCMV-spe- 
cific  memory  CTL  recognizing  all  three  H-2b-restricted 
LCMV  epitopes  could  be  detected  in  CD40L-deficient 
mice 2 mo after infection with this virus, the level of mem- 
ory  CTL  activity in  these  animals was  much  lower  than 
that  exhibited by wild-type mice  at  the  same  time  post- 
infection. 
CTL  memory in  CD40L-deficient  and  wild-type mice 
was also compared in an in vivo assay, in which splenocytes 
were adoptively transferred (without in vitro restimulation) 
from  CD40L-deficient  or  wild-type mice  infected  2  mo 
previously with LCMV into syngeneic wild-type mice per- 
sistently infected with LCMV as a result of neonatal inocu- 
lation  with  the  virus,  and  their  abihty  to  mediate  virus 
clearance from the recipient animals was assessed by com- 
paring the titres of infectious LCMV in the sera of the re- 
cipient animals before and  14 d  after the adoptive transfer. 
The  results  (Table 4)  show  that whereas  adoptive transfer 
of memory CTL from wild-type mice infected 2 mo earlier 
with LCMV into persistently infected recipients led either 
to virus clearance or to  the  death  of the recipient animal, 
mice that received cells from CD40L-deficient donors in- 
fected 2 mo earlier with LCMV neither died nor showed a 
significant decrease in the titres of infectious virus in their 
serum  on  day  14  (or  days 7,  21,  or 28,  data not  shown) 
post-transfer.  Thus,  although  memory  CTLp  clearly were 
present in CD40L-deficient mice 2 mo after infection with 
LCMV (Table 3), they were at too low a frequency to me- 
diate a detectable effect in the in vivo virus clearance assay 
(Table 4). 
After infection  of wild-type mice  with  viruses such  as 
LCMV, virus-specific CTLp reach peak frequencies 7 to 9 d 
post-infection which  decline sharply after virus clearance, 
but  thereafter are maintained at fairly stable levels for the 
lifetime of the  mouse  in the  absence of viral antigen  (57, 
58).  Although the primary CTL response mounted by vi- 
res-infected CD40L-deficient mice was indistinguishable from 
that made by wild-type animals (Table 1) there was a defect 
in the induction and/or maintenance  of CTL  memory in 
CD40L-deficient mice, as the level of virus-specific mem- 
ory  CTL  activity 2  mo  after  infection  with  LCMV  was 
much lower in these mice than  that in wild-type animals. 
Although CD8 +  LCMV-specific primary CTL  can be in- 
duced  in  the  absence  of CD4 +  T  cells,  LCMV-specific 
CD8 +  memory  CTL  are  not  generated/maintained  effi- 
ciently in CD4-deficient mice (59-61).  In the light of our 
recent observation that expression of CD40L is required for 
Table 4.  Memory CTL Activity  in CD4OL-deficient and Wild-type Mice 2 mo after Infection with LCMV, as Assessed by an In Vivo 
Adoptive  Transfer Experiment* 
Recipient Animal 
LCMV titre (PFU/ml) in recipient sera 
Before adoptive transfer  D14 after adoptive transfer 
Recipients given splenocytes 
from LCMV-primed 
wild-type donors 
Recipients given splenocytes 
from LCMV-primed 
CD40L-deficient donors 
W1  5 ￿  104  Mouse died 
W2  1 X  104  <100 
W3  1.4  X  104  Mouse died 
W4  4 X  103  Mouse died 
W5  4.8 X  103  Mouse died 
W6  2.2 x  104  <100 
D1  8 X  10  4  1.2  X  l0  s 
D2  5 X  104  6 x  104 
D3  6 X  104  3.6 X  104 
D4  4 )'( 104  8.5 X  103 
D5  4  X  104  8 X  104 
D6  2.4 X  104  9.8 X  104 
D7  5 X  104  4.2 X  104 
*Erythrocyte-depleted  splenocyte suspensions from CD40L-deficient  and wild-type mice infected 2 mo previously with LCMV were adoptively 
transferred (4 X 107 cells per recipient) into 2-4-too-old hghtly irradiated (300 rads) syngeneic (C57BL/6) wild-type mice in which a persistent in- 
fection with LCMV had been induced by inoculation as neonates with 103 PFU of LCMV Armstrong ic, to determine whether the donor cells ex- 
hibited sufficient LCMV-specific memory CTL activity to mediate virus clearance from the recipient animals. Recipients W1 to W6 received cells 
from wild-type donors, and recipients D1 to D7 received cells from CD40L-deficient  donors. The results shown are the LCMV titres (PFU/ml, 
measured by plaque assay on Vero cells) in the serum of individual recipient mice just before the adoptive transfer was performed,  and on day 14 
(D14) after the adoptive transfer. <100 indicates that no infectious virus was detected in a particular serum sample in the plaque assay, the level of 
sensitivity of which was 100 PFU/ml. Mouse died indicates that the adoptively transferred ceils caused the death of the recipient animal before day 14 
post-transfer. 
2139  Borrow et al. in vivo priming of CD4 + T  cells  (15),  one factor that may 
have  contributed  to  the  defect  in  memory  CTL  activity 
observed after virus infection of CD40L-deficient mice may 
have been a deficit in virus-specific CD4 + T  cell help. 
Alternatively  or in  addition,  our results  may provide  a 
rationale  for the  observation  that  CD40L is  expressed  (at 
low levels) on CD8 + T  cells after activation with anti-CD3 
(1, 6) or PMA/ionomycin (3, 4, 7). It is tempting to specu- 
late  that  CD40L  expression  may be  induced  on antigen- 
specific CD8 + T  cells activated after virus infection in vivo, 
and that a signal delivered via this molecule  (possibly after 
interaction with CD40 expressed on interdigitating cells in 
the  T  cell  zones  of secondary lymphoid  organs  [8])  to  a 
subset  of these  cells  (perhaps  those  expressing  the  highest 
levels of CD40L; or cells that had not migrated into the pe- 
riphery but still remained in the vicinity of CD40-express- 
ing interdigitating cells)  may be involved in the process by 
which  these  cells  are  selected  to  become  memory  CTL. 
Further  if,  as  suggested  by recent  results  of Tough  et  al. 
(Tough,  D.F.,  P.  Borrow,  and J.  Sprent,  manuscript  sub- 
mitted  for  publication),  CD8 +  T  cell  memory  is  main- 
tained  in part  through bystander proliferation  of memory 
CTLp in response to type I interferon production each time 
an unrelated virus infection occurs, a CD40L-mediated in- 
teraction may also be involved in the bystander response of 
memory CD8 + T  cells,  and thus play a critical role in the 
maintenance of CTL memory to viruses. 
Altogether, these studies of the response of CD40L-defi- 
cient mice to virus infection have confirmed the key role of 
CD40L-mediated interactions in thymus-dependent humoral 
immunity. In the absence of CD40L, although some virus- 
specific  IgM  and  IgG2a  production  was  stimulated  by  a 
thymus-independent mechanism,  only a low-titre antiviral 
antibody response  that  decreased  over time  was achieved, 
illustrating  the  necessity for CD40L-mediated  interactions 
for  CD4 +  T  cell-assisted  B  cell  activation  and  isotype 
switching, germinal center formation, production of long- 
lived ASC and the establishment  of B  cell memory to oc- 
cur.  In addition,  they have  revealed  that  although  activa- 
tion  of the  primary virus-specific  CD8 +  CTL  response  is 
not dependent  on CD40L-mediated interactions,  such in- 
teractions are involved in the establishment and/or mainte- 
nance of CTL memory after virus infection. This observa- 
tion may provide a possible rationale for the expression of 
CD40L  on  activated  CD8 +  T  cells,  and  illustrates  that 
CD40L-mediated interactions play a more ubiquitous role 
in the immune system than was previously apparent. A bet- 
ter understanding of the involvement of CD40L-mediated 
interactions in antiviral immunity, particularly in the main- 
tenance of immune memory following virus infection, will 
facilitate the future design of vaccination strategies for viral 
infections,  and  may  also  have  important  implications  for 
the prevention ofimmunopathological responses associated 
with virus infections. 
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